Ultragenyx Pharmaceutical Inc.
RARE
$33.47
$0.100.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.73% | 8.92% | 10.40% | 6.17% | 12.01% |
| Total Depreciation and Amortization | 1.76% | 7.03% | 20.51% | 36.67% | 52.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.53% | -4.70% | 2.62% | -12.73% | -26.55% |
| Change in Net Operating Assets | -118.72% | -5.57% | 140.62% | 192.17% | 168.19% |
| Cash from Operations | -6.47% | 10.27% | 23.34% | 12.77% | 13.02% |
| Capital Expenditure | 32.25% | 42.42% | 75.03% | 83.08% | 87.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 290.20% | -80.17% | -92.34% | -104.84% | -226.87% |
| Cash from Investing | 280.64% | -83.70% | -94.91% | -110.58% | -320.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -87.91% | -87.69% | 1.09% | 1.05% | 1,108.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | 1,009.75% | 25,100.00% | 4,861.90% |
| Cash from Financing | -88.03% | -86.75% | 2.74% | 2.86% | 1,123.05% |
| Foreign Exchange rate Adjustments | 107.71% | 436.60% | 7.01% | -646.54% | 47.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -33.23% | -178.84% | -45.50% | -143.08% | 125.69% |